AzTrials
AzTrials

Tophaceous GoutPhase 3NCT07089888

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

A Phase 3 study testing Allopurinol and Dotinurad in people with Tophaceous Gout, run by Crystalys Therapeutics at 96 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Tophaceous Gout
What is being tested?
Allopurinol and Dotinurad
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
250 participants
Where
96 sitesUnited States
Study dates
4 Aug 2025to 31 Dec 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Between 18 and 75 years of age (inclusive) at the time of signing informed consent.
  • Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria for at least 1 year.
  • Has ≥1 measurable tophus on the hands/wrists and/or feet/ankles between Screening and Day 1. A measurable tophus is defined as ≥5 mm and ≤30 mm in the longest diameter.
  • sUA level ≥5.0 mg/dL at Screening Visit 1 (Day -35 Visit) and Screening Visit 2 (Day -7 Visit).
  • Female participants of childbearing potential must have a negative serum pregnancy test at Screening Visit 1 (Day -35 Visit) and Screening Visit 2 (Day -7 Visit), a negative urine pregnancy test on Day 1, and must not be breastfeeding.
  • Fertile male participants and female participants of childbearing potential must be willing to completely abstain from heterosexual sex or agree to use acceptable contraception from the time of signing informed consent through 30 days after the last dose of study drug.

Who cannot join

  • History of or presence of kidney stones within 1 year prior to Screening.
  • History of or presence of malignancy in the last 5 years other than treated cutaneous basal or squamous cell carcinoma.
  • Hypersensitivity or intolerance to dotinurad or to colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Known or suspected history of drug abuse, a positive drug test at Screening Visit 1, or a recent history of alcohol abuse.
  • Known history of or positive results for human immunodeficiency virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV) during Screening.

Trial locations and contacts

96 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Clinical Trial Lead contact

1-858-379-2316

ClinicalTrials@crystalystx.com

96 sites in 1 country

United States96 sites, 81 recruiting

  • A. Alfred Taubman Health Care Center

    Ann Arbor, Michigan, 48109

    Puja Khanna, 48109

    Recruiting

  • DelRicht Research - Atlanta

    Atlanta, Georgia, 30329

    Withdrawn

  • The Kirklin Clinic of University of Alabama Birmingham Hospital

    Birmingham, Alabama, 35233

    Kenneth Saag, MD

    Recruiting

  • Alabama Clinical Therapeutics

    Birmingham, Alabama, 35235

    Withdrawn

  • Bradenton Research Center

    Bradenton, Florida, 34205

    Eric Folkens, MD

    Recruiting

  • Ellipsis Research Group

    Brooklyn, New York, 11215

    Jorge Serje, MD

    Recruiting

  • DelRicht Research

    Charlotte, North Carolina, 28210

    Olabisi Badmus, MD

    Recruiting

  • Charlottesville Medical Research

    Charlottesville, Virginia, 22911

    James Clark, MD

    Recruiting

  • Chicago Clinical Research Institute, Inc. (CCRII)

    Chicago, Illinois, 60607

    Manognya Sama

    Dennis Levinson, MD

    Recruiting

  • Flourish Chicago - Ravenswood (Great Lakes Clinical Trials)

    Chicago, Illinois, 60640

    Manish Jain, MD

    Recruiting

  • Herco Medical and Research Center, Inc

    Coral Gables, Florida, 33134

    Eddy Capote, MD

    Recruiting

  • Arthritis & Osteoporosis Center of Coastal Bend

    Corpus Christi, Texas, 78415

    Eric Chiang, MD

    Recruiting

  • Medvin Clinical Research - Covina

    Covina, California, 91722

    Samy Metyas, MD

    Recruiting

  • Zenos Clinical Research

    Dallas, Texas, 75230

    Durga Tanneru, MD

    Recruiting

  • Hometown Urgent Care and Research - Dayton

    Dayton, Ohio, 45424

    Steve Choi, MD

    Recruiting

  • Pediatrics & Adult Medicine/SKYCRNG

    Decatur, Georgia, 30034

    Michele Sewell, MD

    Recruiting

  • SKYCRNG - Rophe Adult and Pediatric Medicine

    Decatur, Georgia, 30034

    Dwight Blake, MD

    Recruiting

  • Lone Star Arthritis & Rheumatology Associates - Denton

    Denton, Texas, 76205

    Awilda (Michelle) Luciano, MD

    Recruiting

  • Denver Arthritis Clinic - Lowry

    Denver, Colorado, 80230

    Christopher Antolini, MD

    Recruiting

  • Epic Medical Research - DeSoto

    DeSoto, Texas, 75115

    Haresh Boghara, MD

    Recruiting

  • West Coast Research

    Dublin, California, 94568

    Tim Davis

    Alfred Tan, MD

    Recruiting

  • MediSphere Medical Research Center, LLC - East

    Evansville, Indiana, 47714

    Hubert Reyes, MD

    Recruiting

  • G & L Research

    Foley, Alabama, 36535

    Nidal Morrar, MD

    Recruiting

  • Arizona Arthritis & Rheumatology Associates (AARA) - Gilbert

    Gilbert, Arizona, 85297

    Daniel Kreutz, MD

    Recruiting

  • Arizona Arthritis & Rheumatology Associates (AARA) - Glendale

    Glendale, Arizona, 85306

    Nehad Soloman, MD

    Recruiting

  • Boeson Research - Great Falls

    Great Falls, Montana, 59405

    Richard Horng-Chy Lai, MD

    Recruiting

  • Triad Clinical Trials

    Greensboro, North Carolina, 27410

    Richard Montgomery, MD

    Recruiting

  • DelRicht Research - Hendersonville

    Hendersonville, Tennessee, 37075

    Withdrawn

  • New Generation of Medical Research

    Hialeah, Florida, 32016

    Karelia Ruiz, MD

    Recruiting

  • Best Quality Research

    Hialeah, Florida, 33016

    Gustavo Ledo-Sanchez, MD

    Recruiting

  • Prolato Clinical Research Center

    Houston, Texas, 77027

    Michelle Eisenberg, MD

    Recruiting

  • Pioneeer Research Solutions

    Houston, Texas, 77099

    Mozaffari Shahin

    Francisco Velazquez, MD

    Recruiting

  • Epic Medical Research - Hurst

    Hurst, Texas, 76054

    Robert Strzinek, MD

    Recruiting

  • Delricht Research - Better Life Direct Primary Care

    Indianapolis, Indiana, 46202

    Withdrawn

  • Health Awareness Inc

    Jupiter, Florida, 33458

    Ronald Surowitz, MD

    Recruiting

  • R & H Clinical Research - South Fry Road

    Katy, Texas, 77450

    Maryam Khawari, MD

    Recruiting

  • Clinical Research of Center Florida

    Lakeland, Florida, 33805

    Michael Gimness, MD

    Recruiting

  • Premise Clinical Research Center

    Lancaster, Texas, 75146

    Josier Nisnisan, MD

    Recruiting

  • Alliance Clinical Lewisville (Epic Clinical Research)

    Lewisville, Texas, 75057

    Withdrawn

  • DelRicht Research - Louisville (Derby City DPC)

    Louisville, Kentucky, 40205

    Michael Lovelace, MD

    Recruiting

  • D&H Pompano Research Center

    Margate, Florida, 33063

    Mazyar Rouhani, MD

    Recruiting

  • Delricht Research - Concierge Medicine Of Cincinnati

    Mason, Ohio, 45040

    Withdrawn

  • Southland Arthritis and Osteoporosis Medical Center, Inc

    Menifee, California, 92586

    Amal Mehta, MD

    Recruiting

  • Arizona Arthritis & Rheumatology Associates (AARA) - Mesa

    Mesa, Arizona, 85210

    Swati Bharadwaj, MD

    Recruiting

  • Southwest Rheumatology Research

    Mesquite, Texas, 75150

    Atul Singhal, MD

    Recruiting

  • Tandem Clinical Research - Metairie Clinic

    Metairie, Louisiana, 70006

    Withdrawn

  • Well Pharma Medical Research

    Miami, Florida, 33173

    Eddie Armas, MD

    Recruiting

  • Anchor Medical Research, LLC

    Miami, Florida, 33176

    Juvental Martinez, MD

    Recruiting

  • Panax Clinical Research

    Miami Lakes, Florida, 33014

    Robert G. Perry, MD

    Recruiting

  • DelRicht Research - LCMC Health Urgent Care - Lakeview

    New Orleans, Louisiana, 70124

    Emily Krambeck

    Patrick Dennis, MD

    Recruiting

  • NYU Langone Health

    New York, New York, 10016

    Michael Pillinger, MD

    Recruiting

  • Infinity Clinical Research

    Norco, California, 92860

    Peter Mattar, MD

    Recruiting

  • Coastal Carolina Research Center - Main

    North Charleston, South Carolina, 29405

    Rica Santiago, MD

    Recruiting

  • Las Vegas Clinical Trials

    North Las Vegas, Nevada, 89030

    Alton Walters, MD

    Recruiting

  • Amicis Research Center - Balboa

    Northridge, California, 91324

    Pascal Dabel, MD

    Recruiting

  • Gateway Clinical Trials

    O'Fallon, Illinois, 62269

    Christopher Anderson, MD

    Recruiting

  • Ogden Clinic Canyon View/RIO Clinical Trials

    Ogden, Utah, 84404

    Stephen Bruce, MD

    Recruiting

  • Curalta Clinical Trials

    Oradell, New Jersey, 07649

    Vincent Giacalone, MD

    Recruiting

  • Cure Clinical Research, LLC

    Orange, California, 92866

    Ramprasad (Ram) Dandillaya, MD

    Recruiting

  • Omega Research DeBary

    Orlando, Florida, 32808

    Kwabena Ayesu, MD

    Recruiting

  • Delricht Research - Concierge And Direct Primary Care

    Overland Park, Kansas, 66223

    Jonathan T. Jacobs, MD

    Recruiting

  • MD Medical Research - Oxon Hill

    Oxon Hill, Maryland, 20745

    Stephen Ong, MD

    Recruiting

  • Dream Team Clinical Research

    Pomona, California, 91767

    Withdrawn

  • DelRicht Research - Prairieville

    Prairieville, Louisiana, 70769

    Withdrawn

  • Health Concepts

    Rapid City, South Dakota, 57702

    Richard Beasley, MD

    Recruiting

  • DelRicht Research - Maryland (Matthew L. Mintz, MD, FACP)

    Rockville, Maryland, 20852

    Withdrawn

  • Clinical Research Institute of Michigan - St. Clair Shores

    Saint Clair Shores, Michigan, 48081

    Amar Majjhoo, MD

    Recruiting

  • Discovery Clinical Trials

    San Antonio, Texas, 78229

    Abha Gyani, MD

    Recruiting

  • ERG - Endeavor Clinical Trials

    San Antonio, Texas, 78240

    Nitendra Agarwal, MD

    Recruiting

  • Velocity Clinical Research - San Bernardino

    San Bernardino, California, 92408

    Diana Albay, MD

    Recruiting

  • Acclaim Clinical Research, Inc.

    San Diego, California, 92120

    Julie Vu, MD

    Recruiting

  • East Bay Rheumatology Medical Group

    San Leandro, California, 94578

    Suneet Grewal, MD

    Recruiting

  • Epic Medical Research - San Marcos

    San Marcos, Texas, 78666

    Maria De Jesus Salinas, MD

    Recruiting

  • Shelby Clinical Research, LLC - North Carolina

    Shelby, North Carolina, 28150

    Christian Martin, MD

    Recruiting

  • DM Clinical Research - Detroit

    Southfield, Michigan, 48076

    Withdrawn

  • Premier Health Research

    Sparta, New Jersey, 07871

    Haroon Sarwar, MD

    Recruiting

  • BTC Network - Encompass Clinical Research

    Spring Valley, California, 91978

    Hanid Audish, MD

    Recruiting

  • Delricht Research - Command Family Medicine

    Springfield, Missouri, 65807

    Withdrawn

  • Revival Research Institute - Sterling Heights

    Sterling Heights, Michigan, 48313

    Syed Husain, MD

    Recruiting

  • Siena Research Network

    Sugar Land, Texas, 77479

    Mehjabin Parkar, MD

    Recruiting

  • Clinical Research Trials of Florida

    Tampa, Florida, 33607

    Viviana Fonseca

    Sady Alpizar, MD

    Recruiting

  • Cohen Medical Centers

    Thousand Oaks, California, 91360-3967

    Shariar Cohen-Gadol, MD

    Recruiting

  • DM Clinical Research - Tomball - Multiple Specialties

    Tomball, Texas, 77375

    Shaikh Ali, MD

    Recruiting

  • DelRicht Research - Town and Country

    Town and Country, Missouri, 63017

    Amy E. Roberts, MD

    Recruiting

  • Oakland Medical Center

    Troy, Michigan, 48085

    Jay Sandberg, MD

    Recruiting

  • Del Sol Research Management - Tucson East

    Tucson, Arizona, 85715

    Vicki Kalen, MD

    Recruiting

  • Medvin Clinical Research - Tujunga

    Tujunga, California, 91042

    Withdrawn

  • DelRicht Research - Tulsa

    Tulsa, Oklahoma, 74133

    Withdrawn

  • Preferred Primary Care Physicians - Matthew Drive

    Uniontown, Pennsylvania, 15401

    Christopher Labuda, MD

    Recruiting

  • Gershon Pain Specialists

    Virginia Beach, Virginia, 23454

    Steven Gershon, MD

    Recruiting

  • MedVadis Research

    Waltham, Massachusetts, 02451

    David DiBenedetto, MD

    Recruiting

  • Suburban Research Associates - West Chester Office

    West Chester, Pennsylvania, 19380

    Withdrawn

  • Sahni Rheumatology & Therapy

    West Long Branch, New Jersey, 07764

    Kiren Sahni, MD

    Recruiting

  • Digestive Health Research of North Texas

    Wichita Falls, Texas, 76301

    Vanya Wagler, MD

    Recruiting

  • Rheumatic Disease Associates

    Willow Grove, Pennsylvania, 19090

    Elana Eisner, MD

    Recruiting

  • Conquest Research - Winter Park

    Winter Park, Florida, 32789

    Anand Patel, MD

    Recruiting

Other trials in United States

About this study

Official title: A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Tophaceous Gout

The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.

Conditions
Tophaceous Gout
Being tested
Allopurinol, Dotinurad
Keywords
Tophaceous Gout, Dotinurad, Allopurinol, Hyperuricemia
Medical subject headings
Hyperuricemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AllopurinolDrug

    Over-encapsulated tablets containing active drug substance administered orally (PO).

  • DotinuradDrug

    Over-encapsulated tablets containing active drug substance administered PO.

Study groups in NCT07089888
Study groupRoleWhat they receive
AllopurinolActive comparatorParticipants will discontinue their allopurinol and start on study-supplied allopurinol at the same dose once a day (QD) through Week 76.
Receives: Drug: Allopurinol
DotinuradExperimentalParticipants will discontinue their allopurinol and start dotinurad 1 mg QD for first 4 weeks (Weeks 1-4), dotinurad 2 mg QD for the next 8 weeks (Weeks 5-12), and dotinurad 4 mg QD thereafter up through Week 76.
Receives: Drug: Dotinurad

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24

    Measured: Week 24

Secondary outcomes (16)

  1. Percentage of Participants who Experience Complete Response (CR) or Partial Response (PR) of ≥1 Target Tophus at Week 76

    Measured: Week 76

  2. Percentage of Participants who Experience CR of ≥1 Target Tophus at Week 76

    Measured: Week 76

  3. Percentage of Participants with an sUA Level <4.0 mg/dL at Week 24

    Measured: Week 24

  4. Mean Rate of Gout Flares Requiring Treatment from Week 36 Through Week 76

    Measured: Week 36 through Week 76

  5. Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 and No Gout Flares Requiring Treatment from Week 36 Through Week 76

    Measured: Week 24 and Week 36 through Week 76

  6. Mean Change from Baseline in sUA at Week 24

    Measured: Baseline and Week 24

  7. Mean Percent Change from Baseline in the Sum of the Areas for all Target Tophi at Each Visit

    Measured: Baseline to Week 80

  8. Percentage of Participants who Do Not have a Gout Flare Requiring Treatment from Week 36 through Week 76

    Measured: Week 36 through Week 76

  9. Percentage of Participants with an sUA Level <5.0 mg/dL at Each Visit

    Measured: Up to Week 80

  10. Percentage of Participants with an sUA Level <4.0 mg/dL at Each Visit

    Measured: Up to Week 80

  11. Percentage of Participants with an sUA Level <3.0 mg/dL at Each Visit

    Measured: Up to Week 80

  12. Absolute Change from Baseline in sUA Levels at Each Visit

    Measured: Baseline to Week 80

  13. Percent Change from Baseline in sUA Levels at Each Visit

    Measured: Baseline to Week 80

  14. Percentage of Participants with a Gout Flare Requiring Treatment at Each Month Between Week 24 and the End of Study

    Measured: Week 24 to Week 80

  15. Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)

    Measured: Up to Week 80

  16. Percentage of Participants with Serious Adverse Events (SAEs)

    Measured: Up to Week 80

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jul 2025
  2. Study start4 Aug 2025
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
250 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07089888
Sponsor's protocol ID
FYU-981-CRYS-302
Other IDs
2024-520207-84-00
Status last verified
Oct 2026
First submitted
22 Jul 2025
Last updated
29 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data that underlie the results reported for publication, after deidentification.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Allopurinol and Dotinurad in people with Tophaceous Gout, run by Crystalys Therapeutics at 96 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 96 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Clinical Trial Lead (1-858-379-2316, ClinicalTrials@crystalystx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 (time frame: Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07089888.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in